Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
EPANOVA vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.
Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.
As an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia (≥500 mg/d L)
Treatment of uremic patients undergoing dialysis who require essential amino acid supplementation,Nutritional support in patients with renal insufficiency or failure where nonessential nitrogen sources are contraindicated
4 g orally once daily as 4 capsules of 1 g each with food.
Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.
Terminal elimination half-life approximately 89 hours (range 59–144 hr); allows weekly intramuscular dosing.
Approximately 2-4 hours for most essential amino acids; clinical context: rapid clearance necessitates continuous infusion for stable plasma levels.
Epanova (omega-3-carboxylic acids) is hydrolyzed by pancreatic lipase; free fatty acids are absorbed and then metabolized via beta-oxidation similarly to dietary fatty acids.
Amino acids are metabolized via transamination, deamination, and incorporation into proteins. Hepatic and renal pathways involved in nitrogen disposal and urea cycle.
Primarily hepatic metabolism via omega-oxidation and subsequent conjugation; renal excretion of metabolites: ~15% unchanged in urine; biliary/fecal elimination accounts for ~85% as metabolites.
Renal: >95% as amino acids and metabolites; negligible biliary/fecal.
Highly protein bound (>99%), primarily to albumin and to a lesser extent to alpha-1-acid glycoprotein.
Minimal (<10%) for most amino acids; not significantly protein-bound.
Volume of distribution approximately 0.2 L/kg, indicating limited extravascular distribution.
Approximately 0.2-0.4 L/kg total body water; reflects distribution primarily into extracellular fluid.
Intramuscular: ~100% (absolute bioavailability not determined in humans due to lack of IV formulation; presumed complete absorption from IM site).
Intravenous: 100%.
No dose adjustment required for renal impairment, including end-stage renal disease on dialysis.
For GFR < 30 m L/min: reduce dose to 0.5-0.8 g/kg/day; for GFR < 15 m L/min: 0.3-0.5 g/kg/day; avoid if severe untreated uremia.
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended for severe hepatic impairment (Child-Pugh C) due to lack of data.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated due to risk of hepatic encephalopathy.
Safety and efficacy not established in pediatric patients under 18 years; no recommended dosing.
Infants and children: 1-2 g/kg/day as continuous infusion; neonates: 0.5-1 g/kg/day, titrated to metabolic response.
No specific dose adjustment recommended; use with caution due to increased risk of adverse effects and comorbidities. Monitor hepatic function closely.
Start at 0.6-0.8 g/kg/day; monitor renal function and protein tolerance; adjust for comorbidities like renal impairment or heart failure.
None
Not for intravenous infusion. For oral or enteral use only. Do not administer parenterally.
May increase LDL-C levels; monitor LDL-C during therapy.,May prolong bleeding time; use with caution in patients receiving anticoagulants or with bleeding disorders.,Risk of atrial fibrillation or flutter in patients with prior cardiovascular disease or diabetes; discontinue if symptoms occur.
Monitor serum electrolytes, BUN, and ammonia levels; risk of hyperammonemia in hepatic impairment,Use with caution in patients with metabolic acidosis or fluid overload,May cause gastrointestinal intolerance; adjust rate of administration
Hypersensitivity to Epanova or any of its components.
Hypersensitivity to any component,Phenylketonuria (contains phenylalanine),Severe hepatic failure with hyperammonemia
Epanova may be taken with or without food, but taking with a low-fat meal may improve absorption. Avoid high-fat meals as they can increase GI side effects. Grapefruit juice has no known interaction. No significant food restrictions; maintain a heart-healthy diet.
No specific food interactions. Patients should follow prescribed dietary protein restrictions if indicated (e.g., in hepatic encephalopathy). Avoid alcohol as it may worsen liver function.
Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the human dose (based on body surface area) did not reveal evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk.
Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status directly impacts fetal outcomes.
Excretion into human milk unknown. M/P ratio not available. Caution should be exercised when administered to a nursing mother. Because many drugs are excreted in human milk, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
No data available on milk concentrations. Essential amino acids are normal components of breast milk. Use with caution; benefits likely outweigh risks in malnourished mothers.
No specific dosing adjustments are recommended during pregnancy based on pharmacokinetic changes. The pharmacokinetics of icosapent ethyl have not been studied in pregnant women. Dose should be individualized based on triglyceride levels and tolerability.
Pregnancy increases plasma volume and glomerular filtration rate, potentially altering pharmacokinetics. Monitor clinical response and consider dose adjustments based on metabolic demands; no specific dose adjustment guidelines available.
For patients with severe hypertriglyceridemia (≥500 mg/d L), Epanova (omega-3 carboxylic acids) reduces triglyceride levels by approximately 25-45% at doses of 2-4 g/day. Absorption is enhanced when taken with a low-fat meal; however, if meals cause GI distress, taking with food is still recommended. Avoid use in patients with known fish allergy. Monitor for atrial fibrillation or flutter, especially in elderly patients or those with cardiovascular risk factors. Dose should be adjusted for renal impairment (e GFR <30 m L/min).
Monitor serum ammonia levels in patients with hepatic impairment as essential amino acids may exacerbate hyperammonemia. Use with caution in fluid-restricted patients due to high volume load. Ensure adequate non-protein calories to promote protein synthesis and prevent amino acid catabolism. Do not administer simultaneously with blood products via same IV line.
Take Epanova exactly as prescribed, typically 2-4 capsules once daily with food to reduce GI side effects.,Do not break, crush, or chew the capsules; swallow them whole.,Continue a low-fat diet and exercise program while on this medication.,Inform your doctor if you experience symptoms of an allergic reaction (rash, itching, swelling, severe dizziness, trouble breathing).,Report any irregular heartbeat, chest pain, or shortness of breath immediately.,This medication may increase bleeding risk; tell your doctor if you have a bleeding disorder or take blood thinners (e.g., warfarin).,Store at room temperature away from moisture and heat.
This solution provides essential amino acids to support protein synthesis when you cannot eat enough protein.,It is given intravenously; report any burning, pain, or swelling at the IV site.,Your blood may be monitored for ammonia and electrolyte levels during treatment.,Inform your healthcare provider if you have liver disease, diabetes, or fluid restrictions.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about EPANOVA vs AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE, answered by our medical review team.
EPANOVA is a Parenteral Nutrition Solution that works by Omega-3 fatty acids (EPA and DHA) reduce hepatic very low-density lipoprotein (VLDL) synthesis and increase triglyceride clearance from circulating VLDL particles through activation of lipoprotein lipase.. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is a Parenteral Nutrition Solution that works by Provides essential amino acids and histidine for protein synthesis in patients unable to tolerate oral or enteral nutrition, supporting nitrogen balance and tissue repair. The amino acids are utilized for anabolic processes and metabolic pathways.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between EPANOVA and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of EPANOVA is: 4 g orally once daily as 4 capsules of 1 g each with food.. The standard adult dose of AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is: Intravenous infusion: 500 m L of 5.2% solution (26 g amino acids) over 8-12 hours daily, providing 0.8-1.2 g/kg/day of amino acids depending on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between EPANOVA and AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. EPANOVA is classified as Category C. Pregnancy Category C. In animal reproduction studies, oral administration of icosapent ethyl to pregnant rats and rabbits during organogenesis at doses up to 5 and 7 times the huma. AMINESS 5.2% ESSENTIAL AMINO ACIDS W/ HISTADINE is classified as Category C. Amino acid solutions like Aminess 5.2% are essential for fetal development. No teratogenic effects reported; however, use only if clearly needed as maternal nutritional status dire. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.